MRNA — Moderna, Inc.

Summary of Moderna's Q2 2026 Earnings Call

1. Key Financial Results and Metrics

• Revenue: $145 million for Q2 2026, exceeding guidance and up 2% year-over-year. Total revenue for the first half of 2026 was $500 million.
• Net Loss: $782 million, an improvement of $43 million (5%) compared to Q2 2025. Loss per share was $1.97, compared to $2.13 the previous year.
• Cash and Investments: Ended Q2 with $6.9 billion, down from $7.5 billion at the end of Q1 2026, primarily due to operational funding.
• Cost Management: Reduced cash costs by 10% year-over-year; R&D expenses decreased by 7% to $651 million.

2. Strategic Updates and Business Highlights

• Pipeline Progress:
  • Seasonal flu vaccine mRNA-1010 received a positive recommendation from the U.S. VRBPAC ahead of its PDUFA date on August 5, 2026.
  • Norovirus vaccine mRNA-1403 is preparing to enroll an additional cohort in its Phase III trial.
  • Intismeran, an individualized cancer therapy, showed promising 5-year Phase II data in melanoma, and dosing has begun in new cancer antigen therapy programs.
• Corporate Developments:
  • Expanded partnership with CEPI for an Ebola vaccine.
  • Appointment of Ester Banque as Chief Commercial Officer and Michael McDonnell to the Board of Directors.

3. Forward Guidance and Outlook

• Revenue Growth: Reiterated expectation for up to 10% revenue growth in 2026, with a balanced geographic mix of U.S. and international sales.
• Cost Projections: Lowered cost of sales guidance to $1.7 billion, reflecting manufacturing efficiencies.
• Cash Projections: Expected cash and investments to be between $4.7 billion and $5.2 billion by the end of 2026.

4. Bad News, Challenges, or Points of Concern

• Net Loss: The ongoing net loss indicates continued investment needs and operational challenges.
• Norovirus Vaccine: The Phase III trial did not meet early success criteria at its interim analysis, raising concerns about its efficacy.
• COVID-19 Vaccine Demand: Anticipated declines in COVID vaccination rates could impact revenue, particularly in the U.S.
• Market Dynamics: The company faces competitive pressures in the vaccine market, particularly with emerging products and changing public health needs.

5. Notable Q&A Insights

• Intismeran Interim Analysis: Questions about the statistical powering and expectations for the interim analysis were addressed, with emphasis on the importance of efficacy data and the potential for a nonproportional hazard ratio.
• Flu Vaccine Strain Selection: Discussions with the FDA regarding late strain selection for flu vaccines were confirmed, highlighting Moderna's agility in responding to public health needs.
• Commercial Strategy: Ester Banque's role will focus on managing the growing product pipeline and expanding into new markets, particularly in Europe post-pandemic partnership expiration.
• Norovirus Trial Enrollment: Challenges in achieving primary endpoint cases due to slower epidemiological trends were acknowledged, indicating the need for continued patient enrollment.

This summary encapsulates Moderna's current financial health, strategic initiatives, and challenges as they navigate a competitive landscape while preparing for future growth.